A novel angiotensin I converting enzyme inhibitory peptide from Alaska pollack (Theragra chalcogramma) frame protein hydrolysate.
Alaska pollack frame protein, which is normally discarded as an industrial byproduct in the processing of fish in plants, was hydrolyzed with pepsin. This was fractionated into five major types of Alaska pollack frame protein hydrolysates (APH-I, 10-30 kDa; APH-II, 5-10 kDa; APH-III, 3-5 kDa; APH-IV, 1-3 kDa; and APH-V, below 1 kDa) using an ultrafiltration membrane bioreactor system. Angiotensin I converting enzyme (ACE) inhibitory activities of the fractionated hydrolysates were investigated, and the fraction that exhibited the highest ACE inhibitory activity was further purified using consecutive chromatographic methods on SP-Sephadex C-25 column, Sephadex G-25 column, and high-performance liquid chromatography (HPLC) on an octadecylsilane column. Finally, we purified a novel ACE inhibitory peptide with an IC50 value of 14.7 microM, and the sequence of the peptide was Phe-Gly-Ala-Ser-Thr-Arg-Gly-Ala. In addition, the ACE inhibition pattern of the peptide was found to be noncompetitive.
Je
Jae-Young
JY
Department of Chemistry, Pukyong National University, Busan 608-737, Korea.
Park
Pyo-Jam
PJ
Kwon
Ji Young
JY
Kim
Se-Kwon
SK
D000595:Amino Acid Sequence; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000302:isolation & purification*; D002851:Chromatography, High Pressure Liquid; D029941:Fish Proteins / Q000302:isolation & purification* / Q000378:metabolism; D006868:Hydrolysis; D010434:Pepsin A / Q000378:metabolism; D010446:Peptide Fragments / Q000302:isolation & purification / Q000494:pharmacology
D000806:Angiotensin-Converting Enzyme Inhibitors; D029941:Fish Proteins; D010446:Peptide Fragments; D010434:Pepsin A